Linked Life Data

8365878

Source:http://linkedlifedata.com/resource/pubmed/id/8365878

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1993-10-4
pubmed:abstractText
The effect of systemic recombinant interferon alpha-2a (rIFN-alpha-2a) on the mucocutaneous lesions in Adamantiades-Behçet's disease was assessed in ten patients with the mucocutaneous type of the disease. rIFN-alpha-2a was applied subcutaneously at a dose of 9 x 10(6) IU three times a week for 6 months. Five patients showed a significant reduction in the number, severity, duration and frequency of their mucocutaneous lesions during the treatment compared with the pretreatment phase, whereas in two patients a complete remission and in three patients a partial remission was achieved. In two patients, one with complete and one with partial remission, recurrence of the cutaneous symptoms occurred shortly after discontinuation of the treatment. Renewed administration of rIFN-alpha-2a again led to remission of the symptoms. In another patient with initial partial remission followed by exacerbation, interferon alpha antibodies were detected and the patient responded again when 15 x 10(6) IU rIFN-alpha-2a was administered three times a week. Three patients did not show any change in the characteristics of their lesions, while two patients experienced progression of their disease during treatment. Side-effects were generally mild and well tolerated, but the treatment was discontinued earlier than planned in one patient because of fatigue, myalgia, hypotonus and diarrhoea. Since the classical treatments are generally unsatisfactory, the results of the present study justify the administration of systemic rIFN-alpha-2a in the treatment of the mucocutaneous type of Adamantiades-Behçet's disease.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0017-8470
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
440-5
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
[Adamantiades-Behçet disease. Therapeutic administration of systemic recombinant interferon-alpha-2a].
pubmed:affiliation
Universitäts-Hautklinik und Poliklinik, Klinikum Steglitz Freien Universität Berlin.
pubmed:publicationType
Journal Article, English Abstract